Table 1. Baseline characteristics.
| All Subjects | MACE (+) | MACE (−) | p value | |
|---|---|---|---|---|
| (n = 113) | (n = 19) | (n = 94) | ||
| Male | 54 (47.8%) | 7 (36.8%) | 47 (50.0%) | n.s. |
| Age, yrs | 52.1 ± 15.6 | 61.2 ± 14.2 | 50.3 ± 15.2 | < 0.05 |
| Body mass index, kg/m2 | 23.6 ± 3.2 | 24.1 ± 3.8 | 23.5 ± 3.1 | n.s. |
| Smoking (Current/former) | 32 (30.5%) | 8 (42.1%) | 24 (27.9%) | n.s. |
| Hypertension | 49 (43.4%) | 13 (68.4%) | 36 (38.3%) | < 0.05 |
| Diabetes mellitus | 26 (23.2%) | 9 (47.4%) | 17 (18.3%) | < 0.05 |
| HbA1c, % | 5.9 ± 1.0 | 6.7 ± 1.8 | 5.8 ± 0.7 | < 0.001 |
| Defined mutation | 78 (69.0%) | 15 (78.9%) | 63 (67.0%) | n.s. |
| Lipids | ||||
| Total cholesterol, mg/dl | 385.2 ± 99.1 | 389.9 ± 104.2 | 384.2 ± 98.7 | n.s. |
| LDL-C, mg/dl | 299.0 ± 94.6 | 309.7 ± 113.4 | 296.7 ± 90.9 | n.s. |
| HDL-C, mg/dl | 54.2 ± 13.6 | 49.0 ± 12.8 | 55.3 ± 13.6 | n.s. |
| Triglyceride, mg/dl | 147.5 ± 93.0 | 169.3 ± 85.9 | 142.9 ± 94.4 | n.s. |
| Lp(a), mg/dl | 34.9 ± 36.0 | 34.0 ± 20.2 | 35.1 ± 38.5 | n.s. |
| Post-treatment LDL-C, mg/dl | 140.7 ± 46.4 | 109.2 ± 28.5 | 148.2 ± 46.8 | < 0.05 |
| Percent reduction of LDL-C, % | 52.3 ± 14.6 | 61.5 ± 16.3 | 50.1 ± 13.3 | < 0.05 |
| Statin use | 107 (94.7%) | 18 (94.7%) | 89 (94.7%) | n.s. |
| Ezetimibe use | 51 (45.1%) | 13 (68.4%) | 38 (40.4%) | n.s. |
| Cholestimide use | 19 (16.8%) | 5 (26.3%) | 14 (14.9%) | n.s. |
| ARC positive | 67 (59.3%) | 16 (84.2%) | 51 (54.3%) | < 0.05 |
| ARC score log | 2.9 ± 2.7 | 5.0 ± 2.4 | 2.4 ± 2.6 | < 0.001 |
MACE: major adverse cardiac events, ARC: aortic root calcification